PubMed Update February 2018

36 papers this month. I will add that this is a PubMed literature review – we cover published articles. This month, unfortunately, an unpublished paper of very poor methodology with multiple major errors got a lot of attention. I won’t provide the link here so as to avoid drawing further attention to the paper. It addressed the concept of a “moral hazard” associated with naloxone and, while such a topic could certainly produce a provocative analysis, this paper did not approach science.

 

Onward!

 

1) Simulation of the Effects of Co-Locating Naloxone with Automated External Defibrillators.

Salerno JE, Weiss LS, Salcido DD.

Prehosp Emerg Care. 2018 Mar 1:1-6. doi: 10.1080/10903127.2018.1439128. [Epub ahead of print]

Comments: Not a lot of correlation between AED and naloxone need.

 

2) Fentanyl and heroin contained in seized illicit drugs and overdose-related deaths in British Columbia, Canada: An observational analysis.

Baldwin N, Gray R, Goel A, Wood E, Buxton JA, Rieb LM.

Drug Alcohol Depend. 2018 Feb 20;185:322-327. doi: 10.1016/j.drugalcdep.2017.12.032. [Epub ahead of print]

Comments: More fentanyl around is associated with more deaths.

 

3) National Systematic Legal Review of State Policies on Emergency Medical Services Licensure Levels’ Authority to Administer Opioid Antagonists.

Kinsman JM, Robinson K.

Prehosp Emerg Care. 2018 Feb 27:1-5. doi: 10.1080/10903127.2018.1439129. [Epub ahead of print]

Comments: 49 of 52 US jurisdictions now authorize all levels of emergency responders to administer naloxone.

 

4) Opioid Overdose Education for Individuals Prescribed Opioids for Pain Management: Randomized Comparison of Two Computer-Based Interventions.

Huhn AS, Garcia-Romeu AP, Dunn KE.

Front Psychiatry. 2018 Feb 12;9:34. doi: 10.3389/fpsyt.2018.00034. eCollection 2018.

Comments: Online naloxone education.

 

5) Observational study of dermatological manifestations in patients admitted to a tertiary poison center in Iran

Talaie H, Nasiri S, Gheisari M, Dadkhahfar S, Ahmadi S.

Turk J Med Sci. 2018 Feb 23;48(1):136-141. doi: 10.3906/sag-1707-141.

Comments: Interesting study. Dry skin associated with methadone toxicity. Lead exposure leads to shin hyperpigmentation.

 

6) Dispensing Naloxone Without a Prescription: Survey Evaluation of Ohio Pharmacists.

Thompson EL, Rao PSS, Hayes C, Purtill C.

J Pharm Pract. 2018 Jan 1:897190018759225. doi: 10.1177/0897190018759225. [Epub ahead of print]

Comments: Lots of pharmacists not aware.

 

7) Does training people to administer take-home naloxone increase their knowledge? Evidence from Australian programs.

Dietze PM, Draper B, Olsen A, Chronister KJ, van Beek I, Lintzeris N, Dwyer R, Nelson M, Lenton S.

Drug Alcohol Rev. 2018 Feb 22. doi: 10.1111/dar.12680. [Epub ahead of print]

Comments: Yes.

 

8) Outcomes of compulsory detention compared to community-based voluntary methadone maintenance treatment in Vietnam.

Vuong T, Ritter A, Shanahan M, Ali R, Nguyen N, Pham K, Vuong TTA, Le GM.

J Subst Abuse Treat. 2018 Apr;87:9-15. doi: 10.1016/j.jsat.2018.01.011. Epub 2018 Jan 16.

Comments: Voluntary methadone better than forced treatment. Not much of a surprise here.

 

9) Socioeconomic and geographical disparities in prescription and illicit opioid related overdose deaths in Orange County, California from 2010-2014.

Marshall JR, Gassner SF, Anderson CL, Cooper RJ, Lotfipour S, Chakravarthy B.

Subst Abus. 2018 Feb 21:1-25. doi: 10.1080/08897077.2018.1442899. [Epub ahead of print]

Comments: If you know Orange County, you know it is fascinating to see a report on overdose deaths in Orange County.

 

10) The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and Interventions.

Perlman DC, Jordan AE.

Curr HIV/AIDS Rep. 2018 Feb 19. doi: 10.1007/s11904-018-0390-3. [Epub ahead of print] Review.

Comments: A look at the multiple issues.

 

11) Risk of fentanyl-involved overdose among those with past year incarceration: Findings from a recent outbreak in 2014 and 2015.

Brinkley-Rubinstein L, Macmadu A, Marshall BDL, Heise A, Ranapurwala SI, Rich JD, Green TC.

Drug Alcohol Depend. 2018 Feb 9;185:189-191. doi: 10.1016/j.drugalcdep.2017.12.014. [Epub ahead of print]

Comments: Interesting that risk of death extended past 90 days after release, whereas traditionally the highest risk is in the first week or two.

 

12) Past-Year Nonmedical Use of Prescription Drugs among Women on Probation and Parole: A Cross-Sectional Study.

Hall MT, Ball D, Sears J, Higgins GE, Logan TK, Golder S.

Subst Abus. 2018 Feb 16:1-23. doi: 10.1080/08897077.2018.1442382. [Epub ahead of print]

Comments: Strong associations between opioid use and trauma history.

 

13) Characteristics of adherence to methadone maintenance treatment over a 15-year period among homeless adults experiencing mental illness.

Parpouchi M, Moniruzzaman A, Rezansoff SN, Russolillo A, Somers JM.

Addict Behav Rep. 2017 Sep 23;6:106-111. doi: 10.1016/j.abrep.2017.09.001. eCollection 2017 Dec.

Comments: Poor adherence to methadone among homeless – we need innovative solutions!

 

14) Impacts of an opioid overdose prevention intervention delivered subsequent to acute care.

Banta-Green CJ, Coffin PO, Merrill JO, Sears JM, Dunn C, Floyd AS, Whiteside LK, Yanez ND, Donovan DM.

Inj Prev. 2018 Feb 7. pii: injuryprev-2017-042676. doi: 10.1136/injuryprev-2017-042676. [Epub ahead of print]

Comments: This study didn’t find a significant impact of delivering a brief education-based overdose prevention intervention among a population with extensive morbidity. No surprise to have a study with a negative finding – it expands our knowledge of what can make a difference.

 

15) Pharmaceutical opioid overdose deaths and the presence of witnesses.

Ogeil RP, Dwyer J, Bugeja L, Heilbronn C, Lubman DI, Lloyd B.

Int J Drug Policy. 2018 Feb 9;55:8-13. doi: 10.1016/j.drugpo.2017.12.020. [Epub ahead of print]

Comments: Witnessed overdoses don’t have to result in death.

 

16) Overcoming medication stigma in peer recovery: a new paradigm.

Krawczyk N, Negron T, Nieto M, Agus D, Fingerhood MI.

Subst Abus. 2018 Feb 12:0. doi: 10.1080/08897077.2018.1439798. [Epub ahead of print]

Comments: Yeah – this is a real, and very sad, problem. Imagine a diabetes support group that stigmatized / didn’t allow anyone who took medications for their diabetes.

 

17) The relationship between drug use settings, roles in the drug economy, and witnessing a drug overdose in Baltimore, Maryland.

Latkin CA, Edwards C, Davey-Rothwell MA, Yang C, Tobin KE.

Subst Abus. 2018 Feb 12:0. doi: 10.1080/08897077.2018.1439801. [Epub ahead of print]

Comments: Public drug use.

 

18) Retention of student pharmacists’ knowledge and skills regarding overdose management with naloxone.

Jacobson AN, Bratberg JP, Monk M candidate, Ferrentino J candidate.

Subst Abus. 2018 Feb 12:0. doi: 10.1080/08897077.2018.1439797. [Epub ahead of print]

Comments: Pharmacist student education on overdose and naloxone.

 

19) An opioid overdose curriculum for medical residents: Impact on naloxone prescribing, knowledge, and attitudes.

Taylor JL, Rapoport AB, Rowley CF, Mukamal KJ, Stead W.

Subst Abus. 2018 Feb 12:0. doi: 10.1080/08897077.2018.1439800. [Epub ahead of print]

Comments: Resident education increased prescribing.

 

20) From Peers to Lay Bystanders: Findings from a Decade of Naloxone Distribution in Pittsburgh, PA.

Bennett AS, Bell A, Doe-Simkins M, Elliott L, Pouget E, Davis C.

J Psychoactive Drugs. 2018 Feb 9:1-7. doi: 10.1080/02791072.2018.1430409. [Epub ahead of print]

Comments: People who use opioids are more likely than others to come for a naloxone refill. Consistent with prior studies.

 

21) Commentary on McDonald et al. (2018): Intranasal naloxone-from the laboratory to the real world.

Nielsen S, Larney S, Farrell M.

Addiction. 2018 Mar;113(3):494-495. doi: 10.1111/add.14087. No abstract available.

Comments: Comments on intranasal naloxone.

 

22) High willingness to use rapid fentanyl test strips among young adults who use drugs.

Krieger MS, Yedinak JL, Buxton JA, Lysyshyn M, Bernstein E, Rich JD, Green TC, Hadland SE, Marshall BDL.

Harm Reduct J. 2018 Feb 8;15(1):7. doi: 10.1186/s12954-018-0213-2.

Comments: Fentanyl test strips are in high demand.

 

23) Low-energy Bluetooth for detecting real-world penetrance of bystander naloxone kits: a pilot study.

Lai JT, Chapman BP, Boyle KL, Boyer EW, Chai PR.

Proc Annu Hawaii Int Conf Syst Sci. 2018 Jan 3;2018:3253-3258.

Comments: Hmm. People who got naloxone carried it off the hospital campus – that’s as far as the detector could detect.

 

24) Expected and actual fentanyl exposure among persons seeking opioid withdrawal management.

Kenney SR, Anderson BJ, Conti MT, Bailey GL, Stein MD.

J Subst Abuse Treat. 2018 Mar;86:65-69. doi: 10.1016/j.jsat.2018.01.005. Epub 2018 Jan 4.

Comments: Fentanyl exposure goes further than people who use drugs realize?

 

25) Opioid recovery initiation: Pilot test of a peer outreach and modified Recovery Management Checkup intervention for out-of-treatment opioid users.

Scott CK, Grella CE, Nicholson L, Dennis ML.

J Subst Abuse Treat. 2018 Mar;86:30-35. doi: 10.1016/j.jsat.2017.12.007. Epub 2017 Dec 19.

Comments: Authors report that there’s a high-risk subgroup of people who carry naloxone who don’t engage in treatment.

 

26) Associations between pharmacotherapy for opioid dependence and clinical and criminal justice outcomes among adults with co-occurring serious mental illness.

Robertson AG, Easter MM, Lin HJ, Frisman LK, Swanson JW, Swartz MS.

J Subst Abuse Treat. 2018 Mar;86:17-25. doi: 10.1016/j.jsat.2017.12.003. Epub 2017 Dec 12.

Comments: Big reductions in crisis-driven service utilization.

 

27) Assessment of potential opioid toxicity and response to naloxone by rapid response teams at an urban Melbourne hospital.

Gunasekaran B, Weil J, Whelan T, Santamaria J, Boughey M.

Intern Med J. 2018 Feb;48(2):198-200. doi: 10.1111/imj.13692.

Comments: Authors report variation in naloxone dosing and utilization. I’m not certain that’s a bad thing. There is certainly some variation by provider, but there’s also a lot of variation by situation. Yes, opioid overdose can be simply managed, but if you have the clinical expertise, there’s no reason not to manage it in a more sophisticated, individualized manner.

 

28) Post opioid overdose outreach by public health and public safety agencies: Exploration of emerging programs in Massachusetts.

Formica SW, Apsler R, Wilkins L, Ruiz S, Reilly B, Walley AY.

Int J Drug Policy. 2018 Jan 23;54:43-50. doi: 10.1016/j.drugpo.2018.01.001. [Epub ahead of print]

Comments: Descriptive paper on types of linkage programs after an overdose.

 

29) Reducing opioid overdose in Kazakhstan: A randomized controlled trial of a couple-based integrated HIV/HCV and overdose prevention intervention “Renaissance”.

Gilbert L, Hunt T, Primbetova S, Terlikbayeva A, Chang M, Wu E, McCrimmon T, El-Bassel N.

Int J Drug Policy. 2018 Jan 27;54:105-113. doi: 10.1016/j.drugpo.2018.01.004. [Epub ahead of print]

Comments: Pre-post suggested a reduction in overdose events with naloxone receipt.

 

30) Factors associated with sedative use and misuse among heroin users.

Moses TEH, Lundahl LH, Greenwald MK.

Drug Alcohol Depend. 2018 Feb 2;185:10-16. doi: 10.1016/j.drugalcdep.2017.11.035. [Epub ahead of print]

Comments: Interesting that use of prescribed sedatives was not associated with more problems, but non-medical use was. I wonder what that means in the era when we are rapidly removing benzodiazepines from the medication profiles of any patients who use opioids… is that misguided?

 

31) Naloxone for Opioid Overdose and the Role of the Pharmacist.

Toderika Y, Williams S.

Consult Pharm. 2018 Feb 1;33(2):98-104. doi: 10.4140/TCP.n.2018.98.

Comments: Pharmacists’ role.

 

32) Intravenous fentanyl use among people who inject drugs in Australia.

Geddes L, Iversen J, Memedovic S, Maher L.

Drug Alcohol Rev. 2018 Feb 6. doi: 10.1111/dar.12668. [Epub ahead of print]

Comments: People who inject fentanyl were 2.16 times more likely to report past-year overdose.

 

33) A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: Findings at 12 months post-release.

Brinkley-Rubinstein L, McKenzie M, Macmadu A, Larney S, Zaller N, Dauria E, Rich J.

Drug Alcohol Depend. 2018 Mar 1;184:57-63. doi: 10.1016/j.drugalcdep.2017.11.023. Epub 2018 Jan 31. Erratum in: Drug Alcohol Depend. 2018 Mar 6;186:9.

Comments: All of the findings suggest that continued methadone was superior to detoxing off methadone while in corrections, but the study was almost certainly underpowered to detect a significant difference. The as-treated analysis showed a substantial benefit to continued methadone, but it’s really the intent-to-treat that matters.

 

34) Injectable Extended-Release Naltrexone to Treat Opioid Use Disorder.

Ndegwa S, Pant S, Pohar S, Mierzwinski-Urban M.

CADTH Issues in Emerging Health Technologies. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016-. 163.

Comments: We still have a lot to learn.

 

35) Extended-release injectable naltrexone for opioid use disorder: a systematic review.

Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, Silverman K.

Addiction. 2018 Feb 3. doi: 10.1111/add.14180. [Epub ahead of print] Review.

Comments: Authors determine that lots of people who want to start don’t and those who do often stop treatment early – and there are limited data on efficacy.

 

36) Why It’s Inappropriate Not to Treat Incarcerated Patients with Opioid Agonist Therapy.

Wakeman SE.

AMA J Ethics. 2017 Sep 1;19(9):922-930. doi: 10.1001/journalofethics.2017.19.9.stas1-1709.

Comments: No different from other healthcare.